1. Adı Soyadı: Gül (Atalay) Başaran EK-4 ÖRNEK ÖZGEÇMİŞ 2. Doğum Tarihi: 30.04.1969 3. Unvanı: Profesör 4. Öğrenim Durumu: Derece Alan Üniversite Yıl Lisans / Doktora Tıp Fakültesi İstanbul Üniversitesi Cerrahpaşa İngilizce Tıp Fakültesi 1987-1993 Tıpta Uzmanlık Nöroloji Haseki Devlet Hastanesi 1994-1995 Tıpta Uzmanlık İç Hastalıkları Marmara Üniversitesi Tıp Fakültesi, İç Hastalıkları ABD 1995-1999 Marmara Üniversitesi Yan Dal Tıbbi Onkoloji Tıp Fakültesi İç Hastalıkları ABD 1999-2003 Tıbbi Onkoloji Bilim Dalı Yan Dal Tıbbi Onkoloji Brüksel Üniversitesi (Université Libre de Bruxelles) Jules Bordet Enstitüsü 2001-2003 Tıbbi Onkoloji Bilim Dalı 5. Akademik Unvanlar İç Hastalıkları Uzmanı : 29.06.1999 Tıbbi Onkoloji Yan Dalı Uzmanlık: 15.12.2003 İç Hastalıkları/Tıbbi Onkoloji Doçentlik: 15.04.2005 İç Hastalıkları/Tıbbi Onkoloji Doçentlik Profesörlük: 26.01 2010 6. Yönetilen Yüksek Lisans ve Doktora Tezleri 6.1 Yüksek Lisans Tezleri Çabuk D, Tıbbi Onkoloji Yan Dal Uzmanlık Tezi. Metastatik meme kanseri tanılı
hastaların klinik/patolojik özellikleri ve sağkalım analizleri Marmara Üniversitesi Tıp Fakültesi, Tıbbi Onkoloji Bilim Dalı, İstanbul, 2009 İyikesici S, Tıbbi Onkoloji Yan Dal Uzmanlık Tezi. Meme Kanserinde Her-2/neu ekspresyonu ile pakt, pmapk ve topo II alfa ekspresyonları arasında ilişki Marmara Üniversitesi Tıp Fakültesi, Tıbbi Onkoloji Anabilim Dalı, İstanbul, 2006 6.2 Doktora Tezleri Yok 7. Yayınlar 7.1 Uluslararası hakemli dergilerde yayınlanan makaleler /derlemeler 1. Atalay G, Eksioglu-Demiralp E, Akoglu T, Direskeneli H. The effects of nitric oxide donors and inhibitors on neutrophil functions in Behcet's disease. Clin Exp Rheumatol. 20 (4 Suppl 26):S17-20 (2002). 2. Turhal NS, Gumus M, Atalay G, Aliustaoğlu M, Kabakas F, Karamanoğlu A, Sengoz M. Outpatient care in a Turkish university hospital. Journal of BUON 7:397-398 (2002) 3.Angelo Di Leo, Fatima Cardoso, Virginie Durbecq, Rosa Giuliani, Max Mano, Gul Atalay, Denis Larsimont, Christos Sotiriou, Laura Biganzoli, Martine J. Piccart Predictive molecular markers in the adjuvant therapy of breast cancer :State of the art in the year 2002. Int J Clin Oncol 7,245-253 (2002). 4.Piccart MJ, Cardoso F, Atalay G. Letrozole's superiority over progestins and tamoxifen challenges standards of care in endocrine therapy for metastatic breast cancer. Eur J Cancer. 38 (Suppl 6):S52-4 (2002). 5.Atalay G, Biganzoli L, Renard F, Paridaens R, Cufer T, Coleman R, Calvert AH, Gamucci T, Minisini A, Therasse P, Piccart MJ on behalf of the EORTC Breast Cancer and Early Clinical Studies Groups. Clinical outcome of breast cancer patients with liver metastases alone in the anthracycline-taxane era: a retrospective analysis of two prospective, randomized metastatic breast cancer trials. Eur J Cancer 39, 2439-2449 (2003). 6.Turhal NS, Aliustaoğlu M,Gürses I, Gümüs M, Atalay G, Karamanoglu A, Sengoz M.
Neoplastic diseases prevalence in a Turkish University hospital. Journal of BUON, 8:45-48 (2003). 7.Bonnefoi H, Biganzoli L, Mauriac L, Cufer T, Schaefer P, Atalay G, Piccart M. An EORTC phase I study of capecitabine (Xeloda) in combination with fixed doses of cyclophosphamide and epirubicin (CEX) as primary treatment for large operable or locally advanced/inflammatory breast cancer. Eur J Cancer 39:1277-83 (2003). 8.Awada A, Awada A, Cardoso F, Atalay G et al. The pipeline of new anticancer agents for breast cancer treatment in 2003. Cri rev inonc/hem 48, 45-63 (2003). 9. Atalay G, Dirix L, Biganzoli L, Beex L, Nooij M, Cameron D, Lohrisch C, Cufer T, Lobelle JP, Mattiaci MR, Piccart M, Paridaens R. The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC 10951, Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenapausal patients. Ann Oncol 15: 211-7 (2004). 10. Mano MS, Awada A, Minisini A, Atalay G, Lago LD, Cardoso F, Piccart M. Remaining controversies in the upfront management of advanced ovarian cancer. Int J Gynecol Cancer. 2004 Sep-Oct;14(5):707-20. Review. 11.Minisini A, Atalay G, Bottomley A, Puglisi F, Piccart M, Biganzoli L. What is the effect of systemic anticancer treatment on cognitive function? Lancet Oncology 5, 273-282 (2004). 12.Awada A, Awada A, Cardoso F, Atalay G et al. The pipeline of new anticancer agents for breast cancer treatment in 2003. Cri rev inonc/hem 48, 45-63 (2003). 13.Yumuk PF, Gumus M, Ekenel M, Basaran G, Aliustaoglu M, Topal A, Turhal NS. Attitude toward genetic testing for cancer risk in Istanbul. Genet Test. 2004 Summer; 8(2):169-73 14.Aliustaoglu M, Yumuk PF, Gumus M, Ekenel M, Bolukbas F, Bolukbas C, Mutlu N, Basaran G, Avsar E, Turhal NS. D-dimer--can it be a marker for malignant gastric lesions? Acta Oncol. 2004;43(8):770-1.
15.Yumuk PF, Abacioglu U, Demir G, Cabuk D, Dane F, Gumus M, Ozguroglu M, Ekenel M, Basaran G, Turhal NS. Does the incidence of anal canal cancers differ in Moslem societies? Int J Colorectal Dis. 2005 Jan;20(1):76. 16.Basaran G, Basaran M, Onat H. Chemoradiotherapy for localized non-hodgkin's lymphoma: lessons from old studies. J Clin Oncol. 2005 May 1;23(13):3161-2; author reply 3162-3. 17.Sakar B, Basaran G, Basaran M. Ewing's sarcoma of the rectum: are four cycles of chemotherapy enough? J Clin Oncol. 2005 Aug 20;23(24):5849-50; author reply 5850. 18.Gumus M, Yumuk PF, Atalay G, Aliustaoglu M, Macunluoglu B, Dane F, Caglar H, Sengoz M, Turhal S. What is the optimal number of lymph nodes to be dissected in colorectal cancer surgery? Tumori. 2005 Mar-Apr;91(2):168-72. 19.Gumus M, Yumuk PF, Salepci T, Aliustaoglu M, Dane F, Ekenel M, Basaran G, Kaya H, Barisik N, Turhal NS. HPV DNA frequency and subset analysis in human breast cancer patients' normal and tumoral tissue samples. J Exp Clin Cancer Res. 2006 Dec;25(4):515-21. 20.Atasoy BM, Abacioglu U, Dane F, Ozgen Z, Yumuk PF, Ozden S, Akgun Z, Mayadagli A, Basaran G, Turhal S, Sengoz M. Concomitant administration of uracil-tegafur and leucovorin during adjuvant radiotherapy for locally advanced rectal cancer. J BUON. 2007 Apr-Jun;12(2):203-8. 21.Celikel C, Yumuk PF, Basaran G, Yildizeli B, Kodalli N, Ahiskali R. Epithelioid hemangioendothelioma with multiple organ involvement. APMIS. 2007 Jul;115(7):881-8. Review. 22.Pajk B, Cufer T, Canney P, Ellis P, Cameron D, Blot E, Vermorken J, Coleman R, Marreaud S, Bogaerts J, Basaran G, Piccart M. Anti-tumor activity of capecitabine and vinorelbine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: findings from the EORTC 10001 randomized phase II trial. Breast. 2008 Apr;17(2):180-5. Epub 2007 Oct 31. 23.Ustuner Z, Basaran M, Dizdar Y, Agaoglu FY, Bilgic B, Sakar B, Basaran GA, Darendeliler E, Ozger H, Onat H, Bavbek S. Clinical outcome of rhabdomyosarcoma in
adolescent and adult patients: single center experience from Turkey. Tohoku J Exp Med. 2007 Nov;213(3):221-9. 24.Cabuk D, Basaran G, Celikel C, Dane F, Yumuk PF, Iyikesici MS, Ekenel M, Turhal NS. Vascular endothelial growth factor, hypoxia-inducible factor 1 alpha and CD34 expressions in early-stage gastric tumors: relationship with pathological factors and prognostic impact on survival. Oncology. 2007;72(1-2):111-7. 25.Yumuk PF, Dane F, Yumuk VD, Yazici D, Ege B, Bekiroglu N, Toprak A, Iyikesici S, Basaran G, Turhal NS. Impact of body mass index on cancer development. J BUON. 2008 Jan-Mar;13(1):55-9. 26.Burzykowski T, Buyse M, Piccart-Gebhart MJ, Sledge G, Carmichael J, Lück HJ, Mackey JR, Nabholtz JM, Paridaens R, Biganzoli L, Jassem J, Bontenbal M, Bonneterre J, Chan S, Basaran GA, Therasse P. Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. J Clin Oncol. 2008 Apr 20;26(12):1987-92. 27.Piccart-Gebhart MJ, Burzykowski T, Buyse M, Sledge G, Carmichael J, Lück HJ, Mackey JR, Nabholtz JM, Paridaens R, Biganzoli L, Jassem J, Bontenbal M, Bonneterre J, Chan S, Basaran GA, Therasse P. Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer. J Clin Oncol. 2008 Apr 20;26(12):1980-6. 28.Kuscu MK, Dural U, Onen P, Yaşa Y, Yayla M, Basaran G, Turhal S, Bekiroğlu N. The association between individual attachment patterns, the perceived social support, and the psychological well-being of Turkish informal caregivers. Psychooncology. 2009 Sep;18(9):927-35. 29.Dane F, Ozturk MA, Tecimer T, Atasoy BM, Cabuk D, Yumuk PF, Basaran G, Teomete M, Turhal NS. A case of Kikuchi-Fujimoto disease misdiagnosed as Hodgkin's lymphoma: the importance of second opinion. J BUON. 2009 Apr-Jun;14(2):309-11. 30.Kefeli U, Dane F, Yumuk PF, Karamanoglu A, Iyikesici S, Basaran G, Turhal NS. Prolonged interval in prophylactic heparin flushing for maintenance of subcutaneous implanted port care in patients with cancer. Eur J Cancer Care (Engl). 2009 Mar;18(2):191-4.
31.Yumuk PF, Kefeli U, Ceyhan B, Dane F, Eroglu BT, Gumus M, Cabuk D, Basaran G, Abacioglu U, Turhal NS. Pulmonary toxicity in patients receiving docetaxel chemotherapy. Med Oncol. 2009 Dec 25. [Epub ahead of print] 32.Basaran G, Turhal NS, Cabuk D, Yurt N, Yurtseven G, Gumus M, Teomete M, Dane F, Yumuk PF. Weight gain after adjuvant chemotherapy in patients with early breast cancer in Istanbul Turkey. Med Oncol. 2010 Mar 20. 33.Basaran G, Cabuk D, Cağlar HB, Gulluoğlu B, Kaya H, Seber S, Korkmaz T, Telli F, Kocak M, Dane F, yumuk PF. Clinical outcome of breast cancer patients with N3a (>10 lymph nodes) disease: Has it changed over years? Med Oncol. 2010 Apr 14. 34.Basaran G, Agaoglu F, Basaran M. Doxorubicin, bleomycin, vinblastine, and dacarbazine alone in treatment of favorable, limited-stage Hodgkin's lymphoma: dowe really have robust data? J Clin Oncol. 2010 Sep 20;28(27) 7.2 Uluslararası bilimsel toplantılarda sunulan ve bildiri kitabında (Proceedings) basılan bildiriler 1. The effect of nitric oxide donors and inhibitors on neutrophil functions in Behcet s Disease. Atalay G, Eksioglu-Demiralp E, Direskeneli H. 9 th International Conference on Behcet s Disease, Seoul, Korea May 27-29,2000 (abstract 0110) 2. Outpatient cancer care in a Turkish University Hospital. Turhal S, Kabakas F, Atalay G, Karamanoglu A. Proc Am Soc Clin Oncol 18; a, 1999 (abstract 1652) 3. Outcome of patients after adjuvant treatment for breast cancer. Atalay G,Turhal NS. 11 th International Congress on Anti-Cancer Treatment (ICACT), February 6-9, 2001, Paris, France (selected for oral presentation and received SOMPS poster award) 4. The method of detection and its relationship with the disease stage in Turkish breast cancer patients. Atalay G, Gumus M, Aliustaoglu M, Turhal NS. 1st Congress of International society for breast health. Istanbul, Turkey 21-25 September, 2001. Breast Journal 7 (5) supp Sept/Oct; 2, 2001,4(abstract PP-2) 5. Attitude toward genetic testing in Turkish Society. Mahmut Gümüs, Gül Atalay, Mehmet Aliustaoglu, Senol Güler, Meltem Ekenel, Ayla Karamanoglu, Nazim Serdar
Turhal. ECCO11,the European Cancer Conference Lisbon, 21-25 October,2001 EJC Abstract book 37:S6,S237 (abstract number 874) 6. Outcome of patients after adjuvant treatment in stage B2/C colon cancer. Mahmut Gümüs, Gül Atalay, Mehmet Aliustaoglu, Ayla Karamanoglu, Nazim Serdar Turhal. 12 th Proceeding book of 12 th International Congress on Anti-Cancer Treatment (ICACT), February 4-6, 2002, Paris, Abstract Book, 7. The survival characteristics of the stage IIIB and IV non small cell cancer patients in Marmara University Hospital, Istanbul Mehmet Aliustaoglu, Mahmut Gumus, Gül Atalay, Meric Sengoz, Ufuk Abacioglu, Ayla Karamanoglu, Nazim S Turhal. Proceeding book of 12 th International Congress on Anti-Cancer Treatment, February 4-6, 2002, Paris, Abstract Book, 8. Predictive factors associated with axillary lymph node metastasis (ALNM) in T1, T2, and T3 breast carcinomas. Atalay G, Gumus M, Aliustaoglu M, Turhal NS. 3 rd EBCC Barcelona,19-23 March,2002,Programme and abstract book Eur J Cancer 38 (suppl 3) 2002, S115, abstract 289 9. Outcome of adjuvant treatment in elderly Turkish breast cancer patients. M Aliustaoglu, Atalay G,Gumus M, NS Turhal. Prc Am Soc Clin Oncol 2002,21 259b 10. The extension of nodal sampling in colorectal cancer patients in Marmara University Hospital,Istanbul. M Gumus, Maliustaoglu,, G Atalay, M Beyza, F Dane, HB Caglar, NS Turhal. Proc Am Soc Clin Oncol 2002,21 133b 15. Clinical outcome of breast cancer patients with liver metastases in the anthracyclinetaxane era. Atalay G, Biganzoli K, Renard F, Paridaens R, Batter V, Cufer T, Coleman R, Piccart M,Calvert AH, Gamucci T, Breast Cancer Res Treat 2002;76, S47 16. An EORTC IDBBC-ECSG randomized phase II trial of two different schedules of Caelyx in metastatic breast cancer patients. Coleman R, Biganzoli L, Canney P, Mauriac L, Dirix L,Chollet P, Atalay G, Johnston S, Dittrich C, Piccart M. Breast Cancer Res Treat 2002 76 S132
17. Breast International Group (BIG) survey of medical oncologists attitudes to the management of elderly patients (pts) with early breast cancer. Biganzoli L, Goldhirsch A, Straehle C, Castiglione M, Therasee P, Vogt G, Aapro M, Atalay G, Piccart M. Ann Oncol 2002 13 (suppl 5)9105(abstract 380P) Received best poster award. 18. Atalay, G., Gümüş, M., Aliustaoğlu, M., Abacıoğlu, U., Şengöz, M., Güllüoğlu, B. ve S. Turhal, Outcome of Turkish Breast Cancer Patients Who Received Epirubicin- Based Adjuvant Chemotherapy, 27 th ESMO Congress, Nice, Annals of Oncology, Vol. 13 (Suppl. 5), 44, 156, 2002. 19. Aliustaoglu M., Yumuk F, Gumus M., Ekenel M, Bolukbas F, Bolukbas C, Atalay G., Mutlu N, NS Turhal. Plasma D-Dimer levels in patients with benign and malignant gastric lesions. 27 th ESMO Congress, Nice, Annals of Oncology, Vol. 13 (Suppl. 5), 190, 703P, 2002. 20. Incidence of chemotherapy induced amenorrhea in premenopausal Turkish breast cancer patients. M Ekenel, G Atalay, M Gumus, F Yumuk, M Aliustaoglu, A Karamanoglu, S Turhal. Proceeding Book of 14 th International Congress of Anti- Cancer treatment Paris, 2003, p 159 21. Outcome of breast cancer patients after adjuvant therapy in Istanbul,Turkey M Ekenel, G Atalay, M Gumus, F Yumuk, M Aliustaoğlu, A Karamanoglu, S Turhal. Proceeding Book of 14 th International Congress of Anti-Cancer treatment Paris, 2003, p160. 20. Role of pegylated liposomal doxorubicin (Caelyx) in the treatment of elderly patients with metastatic breast cancer: Safety and activity data from two EORTC studies. Biganzoli l, Coleman R, Minisini A, Hamilton A, Chollet P, Atalay G, Piccart M. Proc of Am Asso Cancer Res 2003,44; 210 (919). 21. F Gündüz, PF Yumuk,F Dane, O Peker, M Ekenel, S İyikesici, G Atalay, NS Turhal. Mantle cell lymphoma presenting as a breast mass.15 th International Congress on anti- Cancer Treatment, Paris, France, February 9-12 th, 2004. 22. F Dane, S İyikesici, M Gümüs, M Ekenel, S İyikeisici, G Atalay, NS Turhal. Adjuvant treatment outcome of high risk stage II and stage III colon cancer patients
treatated in Marmara University Hospital, Istanbul. 15 th International Congress on Anti-Cancer Treatment, Paris, France, February 9 th -12 th, 2004. 15th International Congress on Anti-Cancer Treatment, Proceeding Book, p211, Paris, 2004. 23. G. Atalay, V. Durbecq, D. Larsimont, G. Rouas, A. Di Leo, J.-Y. Leroy, M. J. Piccart; Marmara University Hospital, Istanbul, Turkey; Jules Bordet Institute, Brussels, Belgium The expression pattern of members of the EGFR signaling pathway and its relation with the duration of response in metastatic breast cancer (BC) patients (pts) treated with endocrine therapy (ET). Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 22, No 14S (July 15 Supplement), 2004: 3170 24. Dane, F., Yumuk, P.F., Turhal, N.S., Ekenel, M., Basaran, G., İyikesici, S. ve C. Tecimer, Folfox 4 in metastatic colorectal cancer (MRC) patients who progressed after infusional 5FU/Irinotecan based combination regimens, 40th American Society of Clinical Oncology (ASCO) Annual Meeting, J Clin Oncol, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition), Vol 22, No 14S (July 15 Supplement): 3729, New Orleans, 2004. 25. Aliustaoglu M, Gumus M, Midi A, Celikel CA, Ekenel M, Yumuk F, Ekenel M, Basaran G, NS Turhal. Prognostic values of thymidylate synthase and co-2 expression in colorectal cancer patients tumors. 40th American Society of Clinical Oncology (ASCO) Annual Meeting, J Clin Oncol, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition), Vol 22, No 14S, (July 15 Supplement): 3731, New Orleans, 2004. 26. Cabuk, D., Yumuk, P.F., Abacioglu, U., Demir, G., Dane, F., Gumus, M., Ozguroglu, M., Ekenel, M., Basaran, G. ve N.S. Turhal, Is the incidence of anal cancers different in Moslem societies?, 40th American Society of Clinical Oncology (ASCO) Annual Meeting, J Clin Oncol, 2004 ASCO Annual Meeting Proceedings (Post- Meeting Edition), Vol 22, No 14S, (July 15 Supplement): 4233, New Orleans, 2004. 27. Gumus, M., Yumuk, P.F., Salepci, T., Aliustaoglu, M., Ekenel, M., Basaran, G., Dane, F., Kaya, H., Barisik, N. ve N.S. Turhal, Human papilloma virus: Is it a new etiological factor in breast cancer?, 40th American Society of Clinical Oncology (ASCO) Annual Meeting, J Clin Oncol, 2004 ASCO Annual Meeting Proceedings
(Post-Meeting Edition), Vol 22, No 14S, (July 15 Supplement): 9635, New Orleans, 2004. 28. Dane, F., Turhal, N.S., İyikesici, S., Gumus, M., Yumuk, P.F., Basaran, G., Ekenel, M. ve B. Avery, Clinical features and adjuvant treatment outcomes of colon cancer in two outpatient populations of Knoxville Tennessee and İstanbul Turkey, Ann Oncol, Vienna, Vol. 15(3):355P, iii95, 2004. 29. Iyikesici, S., Turhal, N.S., Yumuk, P.F., Dane, F., Gumus, M., Basaran, G., Ekenel, M. ve B. Avery,. Treatment outcomes in non-small cell lung cancer patients: Comparison between Marmara University, İstanbul Turkey and Knoxville Tennessee, Ann Oncol, Vienna, Vol. 15(3):741P, iii195, 2004. 30. İyikesici, M.S., Kefeli, U., Basaran, G., Dane, F., Ekenel, M., Yumuk, P.F. ve N.S. Turhal, The prognostic impact of body mass index (BMI) in early breast cancer (BC) patient (pts), 41st American Society of Clinical Oncology (ASCO) Annual Meeting, Proceedings ASCO, Volume 23:882, Orlando, 2005. 31. Basaran, G., Dane, F., Iyikesici, S., Ekenel, M., Yumuk, P.F. ve N.S. Turhal, Clinical and pathological characteristics of early breast cancer (EBC) patients <35 years old, 41st American Society of Clinical Oncology (ASCO) Annual Meeting, Proceedings ASCO Volume 23:887, Orlando, 2005. 32. Ekenel, M., Basaran, G., Dane, F., Iyikesici, S., Yumuk, P.F. ve N.S. Turhal, Outcome of adjuvant treatment in elderly Turkish breast cancer patients, 41st American Society of Clinical Oncology (ASCO) Annual Meeting, Proceedings ASCO Volume 23:896, Orlando, 2005. 33. Cabuk, D., Basaran, G., Yumuk, P.F., Celikel, C., Dane, F., İyikesici, M.S., Ekenel, M. ve N.S. Turhal, VEGF, HIF-1 alpha and CD34 expressions in gastric tumors (tms): Relationship with pathological factors and prognostic impact on survival, 41st American Society of Clinical Oncology (ASCO) Annual Meeting, Proceedings ASCO Volume 23:4040, Orlando, 2005. 34. Iyikesici, M.S., Yumuk, P.F., Dane, F., Ekenel, M., Basaran, G. ve N.S. Turhal, Outcome of patients with stage III and IV non-small cell lung cancer in Marmara University Hospital, 11th World Conference on Lung Cancer, Elsevier, Volume 49 Supp 2, S249, Barcelona, 2005.
35. Piccart MJ, Burzykowski T, Sledge G, Carmichael J, Luck HJ, Mackey JR, Naboltz JM, Pariadens R, Biganzoli L, Jassem J, Blohmer JU, Bontenbal M, Bonneterre J, Chan S, Atalay G, Therasse P, Buyse M. Effects of taxanes alone or in combination with athracyclines on yumor response, progression-free survival and ovarall survival in first-line chemotherapy of patients with metastatic breast cancer:an analysis of 4,256 patients randomized in 12 trials., 28th Annual San Antonio Breast Cancer Symposium, December 18-11, 2005 PO 6086 36. Burzykowski T, Piccart MJ Sledge G, Carmichael J, Luck HJ, Mackey JR, Naboltz JM, Pariadens R, Biganzoli L, Jassem J, Blohmer JU, Bontenbal M, Bonneterre J, Chan S, Atalay G, Therasse P, Buyse M. A quantitative study of tumor response and progression-free survival as surrogate endpoints for overll survival in first-line treatment of breast cancer., 28th Annual San Antonio Breast Cancer Symposium, December 18-11, 2005 PO 6084 37. Yumuk, P.F., Yumuk, V.D., Yazici, D., Ege, B., Bekiroglu, N., Dane, F., Iyikesici, S., Basaran, G. ve N.S. Turhal, The impact of body mass index on cancer: A Hospitalbased study, 14th European Congress on obesity, Blackwell Publishing, Volume 6, Supplement 1, Page 82 (Abstract 256), Athens, 2005. 38. Dane, F., Gumus, M., Iyıkesici, S., Yumuk, P.F., Basaran, G., Ozturk, A., Atasoy, B.M., Abacioglu, U., Cabuk, D., Teomete, M. ve N.S. Turhal, Outcome of Rectal Carcinoma Patients receiving adjuvant Chemoradiotherapy, 6th Congress of Balkan Union of Oncology (BUON), Proceedings, PP93, Sofia, 2006. 39. Dane, F., Yumuk, P.F., Gumus, M., Iyıkesici, S., Tufan, A., Basaran, G., Cabuk, D., Ozturk, A., Erdem, R., Teomete, M. ve N.S. Turhal, Outcome of unresectable locally advanced and/or metastatic colorectal cancer patients receiving systemic chemotherapy, 6th Congress of Balkan Union of Oncology (BUON), Proceedings, PP107, Sofia, 2006. 40. Cabuk, D., Basaran, G., Iyikesici, S., Ekenel, M., Dane, F., Teomete, M., Gumus, M., Aliustaoglu, M., Yumuk, F. ve S. Turhal, Outcome of adjuvant treatment in Turkish Breast Cancer (BC) patients (pts): Single Instıtutıon Experience, 31st European Society of Medical Oncology (ESMO) Congress, Ann Oncol. 2006 Sept; 17 (Supp 9): ix109, Abstract 302, İstanbul, 2006.
41. Atalay Basaran G, Guney N, Saip P, Iyikesici S, Kaya H, Yazıcı H, Turhal NS. Serum extracellular domain (ECD) levels, pakt and MAKP expressions as potential markers for response to trastuzumab base therapy in metastatic breast cancer patients: A Turkish Oncology Group Study. Ann Oncol. 2006 Sept; 17 (Supp 9): ix69 ix92, Abstract 230, İstanbul, 2006. 42. Yanmaz MT, Özgüroğlu M, Öztürk B, Uygun K, Basaran G, Turna H, Yıldız Ö, Baran A, Demir G, Büyükünal E. Trastuzumab beyond progression in metastatic breast cancer. Ann Oncol. 2006 Sept; 17 (Supp 9): ix77, Poster 170P, İstanbul, 2006. 43. Yumuk, P.F., Gumus, M., Kaya, H., Alam, K., Dane, F., Gulluoglu, B., Salepci, T., Barisik, N., Basaran, G. ve N.S. Turhal, Association Between Presence Of HPV DNA and P53 In Breast Cancer Patients, 31st European Society of Medical Oncology (ESMO) Congress, Ann Oncol. 2006 Sept; 17 (Supp 9): ix110, Abstract 311, İstanbul, 2006. 44. Basaran, G.A., Cabuk, D., Caglar, H.B., Iyikesici, S., Cakir, T., Gulluoglu, B., Kaya, H., Dane, F., Yumuk, P.F. ve N.S. Turhal, Stage I (T1N0M0) Breast Cancer (BC): Pathological Characteristics and Clinical Outcome, 31st European Society of Medical Oncology (ESMO) Congress, Ann Oncol. 2006 Sept; 17 (Supp 9): ix113, Abstract 320, İstanbul, 2006. 45. Dane, F., Yumuk, F., Gumus, M., Iyikesici, S., Tufan, A., Basaran, G., Cabuk, D., Teomete, M. ve N.S. Turhal, Outcome Of Metastatic Colorectal Cancer Patients Receiving Palliative Chemotherapy in Marmara University Hospital, 31st European Society of Medical Oncology (ESMO) Congress, Ann Oncol. 2006 Sept; 17 (Supp 9): ix129, Abstract 378, İstanbul, 2006. 46. Dane, F., Gumus, M., Yumuk, P.F., Iyikesici, S., Ozturk, A., Basaran, G., Caglar, H.B., Cabuk, D., Teomete, M. ve N.S. Turhal, Outcome Of Colon Cancer Patients Receiving Adjuvant Chemotherapy in Marmara University Hospital, 31st European Society of Medical Oncology (ESMO) Congress, Ann Oncol. 2006 Sept; 17 (Supp 9): ix130, Abstract 384, İstanbul, 2006. 47. Teomete, M., Yumuk, P.F., Iyikesici, M.S., Dane, F., Basaran, G., Cabuk, D., Caglar, H.B., Abacioglu, U ve N.S. Turhal, Outcome of Patients with Stage III and IV nonsmall Cell Lung Cancer in Marmara University Hospital, Istanbul, Turkey, 31st
European Society of Medical Oncology (ESMO) Congress, Ann Oncol. 2006 Sept; 17 (Supp 9): ix225, Abstract 757P, İstanbul, 2006. 48. Dane, F., Topaloglu, N., Abul, Y., Yumuk, P.F., Turhal, N.S., Ceyhan, B., Celikel, T., Caglar, H., Basaran, G. ve R. Ahiskali, Interstitial Pneumonitis Associated with Docetaxel administration, 31st European Society of Medical Oncology (ESMO) Congress, Ann Oncol. 2006 Sept; 17 (Supp 9): ix307, Abstract 1069, İstanbul, 2006. 49. Dane, F., Gumus, M., Iyikesici, S., Yumuk, F., Basaran, G., Atasoy, B., Abacioglu, U., Cabuk, D., Teomete, M. ve S. Turhal, Outcome of rectal carcinoma patients receiving adjuvant chemoradiotherapy in Marmara University Hospital, 42nd American Society of Clinical Oncology (ASCO) Annual Meeting, J Clin Oncol, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement): 13584, Atlanta, 2006. 50. Kefeli, U., Karamanoglu, A., Dane, F., Yumuk, P.F., Iyikesici, M.S., Basaran, G. ve N.S. Turhal, Prolonged interval in Prophylactic Heparin Flushing for Maintenance Subcutaneous Implanted Port Care in Patients with Cancer, 17th International Congress on Anti-Cancer Treatment, Abstract Book Page 348, Paris, 2006. 51. Basaran, G.A., Cabuk, D., Dane, F., Teomete, M., Iyikesici, S., Meltem, E., Gulluoglu, B., Kaya, H., Abacıoglu, U., Yumuk, F. ve S. Turhal, Clinical outcome of node-negative (NN) breast cancer (BC) patients, 43rd American Society of Clinical Oncology (ASCO) Annual Meeting, J Clin Oncol, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement): 11102, Chicago, 2007. 52. Dane, F., Gumus, M., Ozturk, A., Yumuk, F., Iyikesici, S., Basaran, G., Cabuk, D.,Teomete, M. ve N.S. Turhal, Outcome of metastatic colorectal cancer patients receiving second line chemotherapy in Marmara University Hospital, 43rd American Society of Clinical Oncology (ASCO) Annual Meeting, J Clin Oncol, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement): 14588, Chicago, 2007. 53. Gumus, M., Dane, F., Kaya, S., Ozturk, M.A., Yumuk, P.F., Atasoy, B.M., Basaran, G., Salepci, T., Yaylaci, M. ve N.S. Turhal, The role of adjuvant chemoradiotherapy (CRT) in Turkish patients with gastric carcinoma, 43rd American Society of Clinical Oncology (ASCO) Annual Meeting, J Clin Oncol, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement): 15159, Chicago, 2007.
54. Yumuk, P.F., Teomete, M., Dane, F., Cabuk, D., Caglar, H., Abacioglu, U., Basaran, G. ve N.S. Turhal. Outcome of patients with stage III and IV non-small cell lung cancer in Marmara University Hospital, Istanbul, Turkey. 12 th. World Conference on Lung Cancer, Seoul, G.Kore, Journal of Thoracic Oncology, Volume 2, Number 8, Supplement 4, P2-323, August 2007. 55. Dane, F., Gumus, M., Yaman, E., Ozturk, M.A., Sevinc, A., Atasoy, B.M., Cabuk, D., Iyikesici, S., Yumuk, P.F., Basaran, G., Abacioglu, U., Teomete, M. ve N.S. Turhal. Demographical Survival and Prognostic Features of Resected Rectal Cancer in Turkish Patients Population. 18th World Congress of the International Association of Surgeons, Gastroenterologists and Oncologists, İstanbul, Hepato-gastroenterology, Vol. 55, (Suppl. 1), OP70, A28, H.G.E. Update Medical Publishing, Greece, 2008. 56. Cabuk, D., Basaran, G., Teomete, M., Dane, F., Yumuk, P.F. ve N.S. Turhal, Clinical/pathological characteristics of breast cancer (BC) patients (pts) with triplenegative (TN) tumors, 7th Congress of Balkan Union of Oncology (BUON), Proceedings, OP 53, İzmir, 2008. 57. Yumuk, P.F., Teomete, M., Dane, F., Cabuk, D., Basaran, G. ve S. Turhal, Platinum plus vinorelbine (VNR) on days 1 and 8 in advanced non-small cell lung Cancer: Single center results, 7th Congress of Balkan Union of Oncology (BUON), Proceedings, OP 72, İzmir, 2008. 58. Dane, F., Gumus, M., Ozturk, A., Cabuk, D., Basaran, G. ve S. Turhal, Demographics, survival and prognostic features of resected colon Cancer in Turkish patients population, 7th Congress of Balkan Union of Oncology (BUON), Proceedings, OP 92, İzmir, 2008. 59. Dane, F., Ozturk, A., Gumus, M., Yumuk, F., Basaran, G. ve S. Turhal, Survival and prognostic features of stage II and III Rectal Cancer (RC) in Turkish patients population, 7th Congress of Balkan Union of Oncology (BUON), Proceedings, OP 93, İzmir, 2008. 60. Basaran G, Cağlar H, Bese N, Haydaroglu A, Eralp Y, Abalı H. Clinical outcome of T1N0 breast cancer (BC) patients (pts). A Turkish Oncology Group retrospective analysis. 7th Congress of Balkan Union of Oncology (BUON), Proceedings, OP 56, İzmir, 2008.
61. Basaran, G.A., Cabuk, D., Teomete, M., Gulluoglu, B., Kaya, H., Dane, F., Yumuk, P.F. ve N.S. Turhal, Benefit from adjuvant anthracyclines according to hormone receptor status, 44th American Society of Clinical Oncology (ASCO) Annual Meeting, J Clin Oncol 26: 2008 (May 20 suppl; abstr 11513), Chicago, 2008. 62. Dane, F., Gumus, M., Ozturk, M.A., Cabuk, D., Atasoy, B.M., Yumuk, P.F., Basaran, G., Iyikesici, M.S., Teomete, M., Abacioglu, U. ve N.S. Turhal, Clinical features and outcome of adjuvant chemoradiotherapy in Turkish rectal carcinoma patients: single institution experience, 44th American Society of Clinical Oncology (ASCO) Annual Meeting, J Clin Oncol, 26: 2008 (May 20 suppl; abstr 15103), Chicago, 2008. 63. Cabuk, D., Basaran, G., Kaya, H., Gulluoglu, B., Teomete, M., Dane, F., Yumuk, P.F. ve N. S. Turhal, Clinical outcome of triple-negative (TN) breast cancer (BC), 44th American Society of Clinical Oncology (ASCO) Annual Meeting, J Clin Oncol 26: 2008 (May 20 suppl; abstr 11526), Chicago, 2008. 64. Y. Eralp, G. Basaran, M. Dogan, D. Dincol, S. Demirci, F. Icli, H. Onur, P. Saip, E. Topuz, A. Haydaroglu; Istanbul University Institute of Oncology, Istanbul, Turkey; Marmara University, Marmara Medical Faculty, Istanbul, Turkey; Ankara University Medical Faculty, Ankara, Turkey; Ege University, Medical Faculty, Izmir, Turkey The outcome of patients with triple negative breast cancer: Evidence for a favorable ethnic subgroup? The Turkish Oncology Group experience. 2009 ASCO Annual Meeting Proceedings J Clin Oncol 27, 2009 (suppl; abstr e22158) 65. Turhal N, Dane F, Seber S,Korkmaz T, Cabuk D, Basaran G,Yumuk F, Caglar H, Abacıoglu U,Atasoy B. Challenges in applicability of standard treatment for head and neck cancer patients in Istanbul, Turkey.Journal of N.N. Blokhin rusiian Cancer Research Center Rams. Proceedings of the Eurosian Congress on Head&Neck Oncology.16-19 July 2009,Minsk, Republic of Belarus; 20, p 116 66. Basaran G, Okkan S, Caglar H, Benekli M, Haydaroğlu A, Eralp Y, Abalı H, Yıldız F, Beşe N Gursel B, Guney N, Derin D Immunohistochemically defined T1N0 breast cancer subgroups have different clinical outcomes. A retrospective Turkish Oncology Group study. 32nd Annual San Antonio Breast Cancer Symposium, December 9-13, 2009 PO-03 3167
67. Mauriac L, Cameron D, Dirix L, Blot E, Piccart M, Marreaud S, Tjan-Heijnen V, Cufer T, Bogaerts J, Atalay Basaran G. Results of randomized phase II trial combining Iressa (gefitinib) and arimidex in women with advanced breast cancer (ABC). EORTC protocol 10021. 31st Annual San Antonio Breast Cancer Symposium, December 10-14, 2008 PO-06 6133 68. Cabuk D, Basaran G, Korkmaz T, Seber S, Dane F, Telli F, yumuk F, Turhal S. Clinical outcome of Turkish metastatic breast cancer patients with currently available treatment modalities. European Breast Cancer Conference 7, 24-30 March 2010 Barcelona. Eur J Cancer Supplements, Vol. 8, No 3, p205, Poster 498 (2010) 69. Turhal NS, Basaran G, Yurt N, Yurtseven G, Cabuk D, Teomete M, Gumus M. Weight Gain after Adjuvant Chemotherapy in Early Breast Cancer Patients in Istanbul Turkey. American Society of Clinical Oncology 2010 Annual Meeting June 4-8 2010 70. Yılmaz D,B Bingöl İ, Kızıltaç U, Basaran G. Breast cancer prevention. How much do Turkish women know. American Society of Clinical Oncology 2010 Annual Meeting June 4-8 2010 71. Basaran G, Cabuk D, Korkmaz T, Kocar M, Telli F, Dane F, Yumuk F, Turhal S. Clinical, pathological factors predicting early relapse in hormone receptor early breast cancer. BUON Congress 2010, Best Abstracts Presented at BUON Congress 2010,Proceedings Book, 8-11 September 2010, Sibiu, Romania. BA 28, page 13 72. Turhal S, Dane F, Seber S, Korkmaz T, Yumuk F, Kanitez M, Telli F, Kocar M, Basaran G. Tolerability of anthracyclines in Turkish breast cancer patients. BUON Congress 2010, Proceedings Book, 8-11 September 2010, Sibiu, Romania. Oral presentation OP-32, page 14 73. Ozturk MA, Dane F, Karagoz S, Tural D, Demirelli F, Basaran G, Buyukunal E, Mandel NM, Ç Erdamar S, Turna H, Seber S, Turhal S, Serdengecti S. The prognostic value of perineural invasion in patients with early stage colon cancer. BUON Congress 2010, Best Abstracts Presented at BUON Congress 2010,Proceedings Book, 8-11 September 2010, Sibiu, Romania. BA 65, page 23 7.2 Yazılan uluslararası kitaplar veya kitaplarda bölümler
Treatment of Early Stage Breast Cancer: Node positive breast cancer. G.Atalay, C Lohrisch, M Piccart. In, Breast Cancer Management: Application of Evidence to Patient Care. Second edition. Edited by JM Nabholtz, K Tonkin, MS Aapro, AU Buzdar. Martin Dunitz Ltd, London U.K., 2003 7.3 Ulusal hakemli dergilerde yayınlanan makaleler/derlemeler 1.Atalay G, Ratip S, Caymaz O, Oktay A, Bayık M. Pancytopenia secondary to ticlopidine. Case Report. Turkish Hematology Oncology Journal 2:12,1999 2.Gul Atalay, Serdar Turhal. Hıçkırık, disfaji, ve dispepsi. Kanserli hastada ağrı dışı semptomların palyasyonu. Hematoloji-Onkoloji Güncel Derleme Dergisi Cilt 3, sayı 3, 236-239, 2001 3.Başaran G, Ekenel M, Demirkalem P, Çakır T, Güllüoğlu B, Gümüş M, Dane F, İyikesici S, Kaya H,Yumuk F, Turhal NS.Evre I (T1N0M0) meme kanseri:patolojik özellikler ve klinik sonuçlar Evre I (T1N0M0) meme kanseri: Patolojik özellikler ve klinik sonuçlar. Tıbbi Onkoloji Dergisi. Cilt 19, sayı 2, 53-58, 2004 4. P Fulden Yumuk, M Salih İyikesici, Mahmut Gümüş,, Mehmet Aliustaoğlu, Faysal Dane, Gül Başaran, Meltem Ekenel, Ufuk Abacıoğlu, N Serdar Turhal. Kemoterapi verilen lokal ileri ve metastatik küçük hücreli dışı akciğer kanseri hastalarımızın sağkalım ve prognostik açıdan değerlendirilmesi. Tıbbi Onkoloji Dergisi Cilt 19, sayı 3, 106-111, 2004 5.Basaran G. Kanser hastalarında Beslenme. Kanserde Destek Tedavisi ve Palyatif Bakım Özel Sayısı, Türkiye Klinikleri Cilt 17, sayı 1, 24-32, 2004 6. Basaran M, Basaran G. Onkolojik Aciller. Kanserde Destek Tedavisi ve Palyatif Bakım Özel Sayısı, Türkiye Klinikleri Cilt 17, sayı 1, 16-19, 2004 7.Gul Başaran, Devrim Çabuk. Meme Kanserinde adjuvan sistemik tedavi ilkeleri. Türkiye Klinikleri, Tıbbi Onkoloji Cilt 1, sayı 1, sayfa 23-46, 2008 8.Gul Başaran. Trastuzumab Farmakolojik özellikleri ve klinik gelişimi. Trastuzumab eki, Remisyon Güncel Onkoloji Dergisi, cilt 10, sayı 3,sayfa 1-6, 2010
7.5 Ulusal bilimsel toplantılarda sunulan ve bildiri kitabında basılan bildiriler 1. Gumus, M., Atalay, G., Aliustaoglu, M., Karamanoglu, A., Dane, F. ve N.S. Turhal. Marmara Üniversitesi Hastanesi nde izlenen evre II ve evre III kolon kanserli hastaların değerlendirilmesi. XIV. Ulusal Kanser Kongresi (Uluslararası katılımlı), Bildiri Özetleri, SB-14, s: 84, İstanbul, 2001. 2. Aliustaoğlu M., Atalay, G., Gümüş, M., Karamanoglu, A., Dane, F. ve N.S. Turhal. Marmara Üniversitesi Hastanesi nde izlenen evre III ve evre IV akciğer kanserli hastaların değerlendirilmesi. XIV. Ulusal Kanser Kongresi (Uluslararası katılımlı), Bildiri Özetleri, PO-5, s: 187, İstanbul, 2001. 3. Gumus, M., Atalay, G., Aliustaoglu, M., Karamanoglu, A., Dane, F. ve N.S. Turhal. Marmara Üniversitesi Hastanesi nde izlenen evre IV kolon kanserli hastaların değerlendirilmesi. XIV. Ulusal Kanser Kongresi (Uluslararası katılımlı), Bildiri Özetleri, SB-14, s: 85, İstanbul, 2001. 4. Abacıoğlu, U., Şengöz, M., Çağlar, H., Gümüş, M., Atalay, G. ve S. Turhal. Rektum ve Rektosigmoid Kanserlerinde Adjuvan Kemoradyoterapi Sonuçları. XIV. Ulusal Kanser Kongresi, Bildiri Özetleri Kitapçığı, 64, SB-07, İstanbul, 2001. 5. Ekenel M, Basaran Atalay G, Gümüş M, Aliustaoğlu M, Dane F, Yumuk F, Turhal NS. Premenopozal meme kanseri hastalarında kemoterapiye bağlı amenore insidansı ve prognsotik rolü. VII. Ulusal Meme Hastalıkları Kongresi. 16-19 ekim 2003, antalya, Kurs ve Bildiri Özet Kitabı, 170; P82, 2002 6. Erbarut İ, Kaya H, Başaran G, Güllüoğlu B. Memenin apokrin karsinomunda hormon reseptörleri ve onkogenlerin ekspresyonu XVII Ulusal Patoloji Sempozyumu, 1-6 Ekim 2004, Bildirir Kitabı s 213-214, Gaziantep. 7. Yumuk PF, İyikesici S, Gümüş M, Aliustaoğlu M, Dane F, Başaran G, Ekenel M, Abacıoğlu U, Turhal NS. Kemoterapi verilen lokal ileri ve metastatik küçük hücreli dışı akciğer kanseri hastalarının sağkalım ve prognostik açıdan değerlendirilmesi. 1.
Ulusal Torasik Onkoloji Konresi, Final Program ve Bildiri Özet Kitabı, S79 Antalya, 2004. 8. Dane, F., Gümüş, M., İyikesici, S., Yumuk, F., Öztürk, A., Başaran, G., Çabuk, D. ve S. Turhal. Adjuvan Kemoterapi alan Kolon Kanseri Hastalarının Sağkalım ve Prognostik Açıdan Değerlendirilmesi. 1. Tıbbi Onkoloji Kongresi, Bildiri Özet Kitabı, P066, Antalya, 2006. 9. Çabuk, D., Başaran, G., Yumuk, F., Çelikel, Ç., Dane, F., İyikesici, S., Ekenel, M. ve S. Turhal. Mide kanserinde VEGF, HIF 1 Alfa, CD34 ekspresyonu ve bu faktörlerin prognostik önemi. 1. Tıbbi Onkoloji Kongresi, Bildiri Özet Kitabı, SB03 (Sözlü Sunum), Antalya, 2006. 10. Dane, F., Yumuk, F., İyikesici, S., Gümüş, M., Tufan, A., Başaran, G., Teomete, M. ve S. Turhal. Palyatif Kemoterapi alan metastatik kolorektal kanser hastalarının sağkalım sonuçları. 1. Tıbbi Onkoloji Kongresi, Bildiri Özet Kitabı, SB42 (Sözlü Sunum), Antalya, 2006. 11. Dane, F., Gümüş, M., İyikesici, S., Yumuk, F., Başaran, G., Atasoy, B., Abacıoğlu, U. ve S. Turhal. Adjuvan kemoradyoterapi verilen Evre II/III rektum kanseri hastalarının sağkalım ve prognostik açıdan değerlendirilmesi. 1. Tıbbi Onkoloji Kongresi, Bildiri Özet Kitabı, SB45 (Sözlü Sunum), Antalya, 2006. 12. Güllüoğlu BM, Sarıkaya Ö, Dede F, Barlas A, Bayramiçli M, Çağlar H, Yumuk F, Başaran GA, Kaya H, Aktan AÖ. Marmara Üniversitei Tıp Fakültesi Genel Cerrahi Uzmanlık Eğitimi içerisinde multidisipliner meme ve endokrin cerrahisi eğitimi; Eğitim Kalitesi ve Öğrenci memnuniyetini arttırabilmek için bir model. IV. Ulusal Tıp Eğitimi Kongresi, Özet Kitabı, 78, B12; 2-5 Mayıs 2006, Çukurova Üniversitesi Tıp Fakültesi Adana 1. Gümüş, M., Dane, F., Kaya, S., Öztürk, M.A., Yumuk, P.F., Atasoy, B.M., Başaran, G., Salepçi, T., Yaylacı, M. ve N.S. Turhal. Mide Kanserinin Adjuvan Tedavisinde Kemoradyoterapinin Etkinliği. 17.Ulusal Kanser Kongresi, Bildiri Özet Kitabı, Ref No: 774 Antalya, 2007. 2. Öztürk, A., Dane, F., Tecimer, T., Atasoy, B., Çabuk, D., Yumuk, P.F., Başaran, G., Teomete, M. ve N.S.Turhal. Onkoloji Kliniğine Refere Edilen Selim bir
Lenfadenopati Nedeni: Kikuchi-Fujimoto Hastalığı. Kongresi, Bildiri Özet Kitabı, B62, Antalya, 2007. 4.Ulusal Tıbbi Onkoloji 13. Dane, F., Gümüş, M., Öztürk, M.A., Atasoy, B.M., İyikesici, S., Yumuk, P.F., Başaran, G., Abacıoğlu, U., Çabuk, D.Ö., Teomete, M. ve N.S. Turhal. Rektum Kanseri Olgularının Klinik Özellikleri ve Adjuvan Kemoradyoterapi Sonuçları: Tek Merkez Tecrübesi. 2.Tıbbi Onkoloji Kongresi, Bildiri Özet Kitabı, P23, Antalya, 2008. [Poster Bildiri Ödülü] 14. Dane F, Gümüş M, Yaman E, Öztürk MA, Sevinç A, Atasoy BM, Çabuk D, İyikesici S, Yumuk PF, Başaran G, Abacıoğlu U, Teomete M, Turhal NS. Türk Toplumunda Rektum Kanserli Hastaların Demografik, Histopatolojik Özellikleri, Sağ Kalım ve Prognostik Faktörler. 5. Ulusal Tıbbi Onkoloji Kongresi, Bildiri Özet Kitabı, B42, Antalya, 2008. 15. Sarıkaya Ö, Atasoy BM, Çağlar HB, Güllüoğlu B, Dede F, Öneş T, Yumuk F, Başaran G, Dane F, Abacıoğlu U. Probleme dayalı öğrenmede performans değerlendirme. Ulusal Tıp Eğitimi Kongresi, Program, Bildiri ve Konuşma Özetleri Kitabı 76, İzmir 2008. 16. Özden Özer, Bugu Usanma, Gul Basaran, Mustafa Çetiner. Akut Lösemiyi taklit eder tarzda kemik iliği infiltratı olarak ortaya çıkan rhabdomyosarkom:bir olgu sunumu. XXXIV Ulusal Hematoloji Kongresi Bildiri Kitabı Metni BO17, bildiri 335, 08-11 Ekim 2008, Çeşme, İzmir 17. Öztürk, M.A., Dane, F., Çelikel, Ç.A., Baş, E., Çabuk, D., Yumuk, P.F., Başaran, G.A., Teomete, M. ve N.S. Turhal. Adjuvan Kemoradyoterapi alan Kolorektal Kanser Hastalarında Survivinin Prognostik Önemi. 18. Ulusal Kanser Kongresi, Bildiri Özet Kitabı, P135, Antalya, 2009. 18. Yılmaz D, Bingöl İ, Kızıltaç U, Bayırlı H. Danışman :Gül Başaran. Meme Kanserinden Korunma: Türk Kadınları ne kadar bilinçli? MASCO 21-23 Mayıs 2009, Sözel Bildiriler, sayfa 21, Sözel sunum 12, Marmara Üniversitesi Haydarpaşa Yerleşkesi, İstanbul.